Do analysts rate LNAI or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, LNAI or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is LNAI or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Invizyne Technologies N/A N/A N/A

Do analysts rate LNAI or GOSS?

Gossamer Bio has a consensus target price of $256.00, suggesting a potential upside of 2,366.28%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Is LNAI or GOSS more profitable?

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Gossamer Bio -235.00% N/A -112.04%

Do analysts prefer LNAI or MREO?

Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 484.80%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Is LNAI or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Mereo BioPharma Group N/A -74.82% -64.28%

Do analysts prefer MDXH or LNAI?

MDxHealth currently has a consensus price target of $2.17, indicating a potential upside of 221.85%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MDXH or LNAI more profitable?

Lunai Bioworks has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% Lunai Bioworks N/A -1,243.45% -1,617.76%

Lunai Bioworks (LNAI) Competitors

$2.19 +0.02 (+0.92%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.30 +0.11 (+5.02%)

As of 07:29 AM Eastern

Compare

LNAI vs. IZTC, GOSS, MREO, ALGS, and MDXH

Should you buy Lunai Bioworks stock or one of its competitors? Lunai Bioworks's main competitors and comparable companies include Invizyne Technologies (IZTC), Gossamer Bio (GOSS), Mereo BioPharma Group (MREO), Aligos Therapeutics (ALGS), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lunai Bioworks compare to Invizyne Technologies?

Lunai Bioworks (NASDAQ:LNAI) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. Lunai Bioworks' average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Invizyne Technologies	Neutral

71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies' return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Invizyne Technologies	N/A	N/A	N/A

Summary

Lunai Bioworks beats Invizyne Technologies on 4 of the 6 factors compared between the two stocks.

How does Lunai Bioworks compare to Gossamer Bio?

Lunai Bioworks (NASDAQ:LNAI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, Gossamer Bio had 8 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Gossamer Bio and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat Gossamer Bio's score of -0.06 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Gossamer Bio	Neutral

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lunai Bioworks has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Gossamer Bio has a consensus target price of $256.00, suggesting a potential upside of 2,366.28%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Gossamer Bio has higher revenue and earnings than Lunai Bioworks. Gossamer Bio is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Gossamer Bio	$48.47M	0.63	-$170.37M	-$0.70	N/A

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Gossamer Bio	-235.00%	N/A	-112.04%

Summary

Gossamer Bio beats Lunai Bioworks on 12 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to Mereo BioPharma Group?

Lunai Bioworks (NASDAQ:LNAI) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Lunai Bioworks has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Mereo BioPharma Group's return on equity of -74.82% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. Mereo BioPharma Group's average media sentiment score of 1.89 beat Lunai Bioworks' score of 1.87 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has higher revenue and earnings than Lunai Bioworks. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Mereo BioPharma Group	$500K	91.02	-$41.88M	-$0.04	N/A

Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 484.80%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Mereo BioPharma Group beats Lunai Bioworks on 10 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Lunai Bioworks has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

In the previous week, Aligos Therapeutics had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Aligos Therapeutics and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat Aligos Therapeutics' score of 0.63 indicating that Lunai Bioworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Lunai Bioworks	Very Positive

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 671.54%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aligos Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Aligos Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.22	-$24.19M	-$7.30	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aligos Therapeutics beats Lunai Bioworks on 12 of the 16 factors compared between the two stocks.

How does Lunai Bioworks compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, MDxHealth had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 2 mentions for MDxHealth and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat MDxHealth's score of 0.94 indicating that Lunai Bioworks is being referred to more favorably in the news media.

Company	Overall Sentiment
MDxHealth	Positive
Lunai Bioworks	Very Positive

Lunai Bioworks has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

MDxHealth has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.31	-$33.52M	-$0.72	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

71.4% of Lunai Bioworks shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MDxHealth currently has a consensus price target of $2.17, indicating a potential upside of 221.85%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MDxHealth has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Summary

MDxHealth beats Lunai Bioworks on 11 of the 15 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.84M	$3.89B	$7.21B	$15.01B
Dividend Yield	N/A	3.65%	2.57%	12.21%
P/E Ratio	-5.48	14.11	272.90	25.31
Price / Sales	N/A	1,457.03	708.39	112.43
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	-0.22	15.44	10.46	6.18
Net Income	-$178.01M	-$22.78M	$3.49B	$357.96M
7 Day Performance	-16.09%	-0.68%	-0.76%	-0.56%
1 Month Performance	-1.35%	0.33%	-0.39%	-3.62%
1 Year Performance	N/A	39.46%	18.93%	6.05%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.3241 of 5 stars	$2.19 +0.9%	N/A	N/A	$9.84M	N/A	N/A	20	Positive News
IZTC Invizyne Technologies	N/A	$6.85 +0.7%	N/A	-49.4%	$42.83M	N/A	N/A	29
GOSS Gossamer Bio	2.3551 of 5 stars	$0.18 -0.2%	$3.20 +1,725.4%	-95.9%	$41.14M	$48.47M	N/A	180
MREO Mereo BioPharma Group	3.8375 of 5 stars	$0.25 -8.2%	$1.67 +566.7%	-83.8%	$39.92M	$500K	N/A	40	Positive News
ALGS Aligos Therapeutics	2.5976 of 5 stars	$6.21 -0.2%	$38.50 +520.0%	-46.7%	$38.78M	$2.19M	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. IZTC, GOSS, MREO, ALGS, and MDXH

How does Lunai Bioworks compare to Invizyne Technologies?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Summary

How does Lunai Bioworks compare to Mereo BioPharma Group?

Summary

How does Lunai Bioworks compare to Aligos Therapeutics?

Summary

How does Lunai Bioworks compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. IZTC, GOSS, MREO, ALGS, and MDXH

How does Lunai Bioworks compare to Invizyne Technologies?

Does the media favor LNAI or IZTC?

Do insiders & institutionals have more ownership in LNAI or IZTC?

Which has stronger valuation and earnings, LNAI or IZTC?

Do analysts rate LNAI or IZTC?

Is LNAI or IZTC more profitable?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Does the media prefer LNAI or GOSS?

Do insiders & institutionals have more ownership in LNAI or GOSS?

Which has more volatility & risk, LNAI or GOSS?

Do analysts rate LNAI or GOSS?

Which has better earnings and valuation, LNAI or GOSS?

Is LNAI or GOSS more profitable?

Summary

How does Lunai Bioworks compare to Mereo BioPharma Group?

Which has more volatility and risk, LNAI or MREO?

Is LNAI or MREO more profitable?

Do insiders & institutionals believe in LNAI or MREO?

Does the media refer more to LNAI or MREO?

Which has stronger valuation & earnings, LNAI or MREO?

Do analysts prefer LNAI or MREO?

Summary

How does Lunai Bioworks compare to Aligos Therapeutics?

Is ALGS or LNAI more profitable?

Does the media prefer ALGS or LNAI?

Do analysts recommend ALGS or LNAI?

Which has more risk & volatility, ALGS or LNAI?

Which has stronger earnings & valuation, ALGS or LNAI?

Do insiders & institutionals hold more shares of ALGS or LNAI?

Summary

How does Lunai Bioworks compare to MDxHealth?

Does the media favor MDXH or LNAI?

Is MDXH or LNAI more profitable?

Which has better earnings & valuation, MDXH or LNAI?

Do institutionals and insiders hold more shares of MDXH or LNAI?

Do analysts prefer MDXH or LNAI?

Which has more volatility and risk, MDXH or LNAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools